14-day Premium Trial Subscription Try For FreeTry Free
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today reported financial and operating r
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively onlin
The Global Hematopoietic Stem Cells Transplantation (HSCT) Market will grow by USD 4.64 bn during 2020-2024
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that it will report its
We think intelligent long term investing is the way to go. But along the way some stocks are going to perform badly...
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Wednesday, Zacks.com reports. Accor
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced that as a result of cont
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medic
JPMorgan Chase & Co. increased its stake in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) by 26.1% during the 1st quarter, according to its most recent filing with the Securities & Exchange Comm
Lineage Cell Therapeutics is developing therapies to address serious unmet needs in dry AMD and spinal cord injuries as well as developing a potential cancer va
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Avid Bioservices
In a report released today, Keay Nakae from Chardan Capital reiterated a Hold rating on OncoCyte (OCX – Research Report),
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Lineage Cell Therapeutics (LCTX – Research Report) on June 25
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE